(Q24246319)

https://api.crossref.org/works/10.1002%2F14651858.CD006391

Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

Weight Changes With Schizophrenic Psychosis and Psychotropic Drug Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

Laboratory Changes with Chlordiazepoxide and Thioridazine, Alone and Combined

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

Acute high-dose parenteral haloperidol treatment of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

Effect of the benzodiazepine derivative estazolam in patients with auditory hallucinations. A multicentre double-blind, cross-over study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

Clonazepam and phenobarbital in tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative schizophrenic symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

Diazepam in schizophrenia: a preliminary double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

Clonazepam treatment of chronic schizophrenia: negative results in a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

Anxiety in schizophrenia. The responses to chlordiazepoxide in an intensive design study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

Placebo response in refractory tardive akathisia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

When Symptoms Persist: Choosing Among Alternative Somatic Treatments for Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

A revision of the psychiatric rating scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

THE NURSES' OBSERVATION SCALE FOR INPATIENT EVALUATION: A NEW SCALE FOR MEASURING IMPROVEMENT IN CHRONIC SCHIZOPHRENIA

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Clozapine versus typical neuroleptic medication for schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Carbamazepine for schizophrenia and schizoaffective psychoses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Lithium for schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Valproate for schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Beneficial effect of high-dose clotiazepam on intractable auditory hallucinations in chronic schizophrenic patients. An open trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

A double-blind outpatient study of diazepam (Valium) and placebo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Prophylactic effect of neuroleptics in symptom-free schizophrenics.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

High doses of diazepam improve neuroleptic-resistant chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

The unit of analysis error in studies about physicians' patient care behavior

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Dropout rates in randomised antipsychotic drug trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Treatment of long-term tardive dyskinesia with vitamin E.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Itil TM, Keskiner A, Fink M: Thioridazine and chlordiazepoxide, alone and combined, in the treatment of chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Diazepam in high doses is effective in schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Chemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Evidence of ten psychotic syndromes.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Double blind, controlled study of the efficacy and safety of alpidem in the treatment of anxiety in schizophrenic in-patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Acute effects of the synthetic analogue of methionine enkephalin FK 33-824 in schizophrenic patients. A double blind trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Development of a scale for assessment of agitation following traumatic brain injury

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

A double-blind comparison of clonazepam and placebo in the treatment of neuroleptic-induced akathisia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

The effect of benzodiazepines on tardive dyskinesia symptoms

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

A controlled long-term study of flunitrazepam, nitrazepam and placebo, with special regard to withdrawal effects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Clonazepam/haloperidol combination therapy in schizophrenia: a double blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Analgesic and euphoric effects of high dose diazepam in schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Adjunctive benzodiazepines in acute schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Effects of Control Techniques on Therapeutic Outcome in a Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Treatment of catatonia with low-dose lorazepam

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

A reference study of ataraxics. A two-week double blind outpatient evaluation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Diazepam in tardive dyskinesia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Behavioral side effects of triazolam in psychiatric inpatients: report of five cases.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Schizophrenics Fully Remitted on Neuroleptics for 3–5 years—To Stop or Continue Drugs?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021

Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391

7 January 2021